Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters
1997

Iododeoxyuridine in Glioma Spheroids for Radiotherapy

publication Evidence: moderate

Author Information

Author(s): A Neshasteh-Rizl, WJ Angerson, JR Reeves, G Smith, R Rampling, RJ Mairs

Primary Institution: University of Glasgow

Hypothesis

The study investigates the limitations of IUdR-targeted Auger electron therapy for glioma due to cellular proliferation heterogeneity.

Conclusion

The study suggests that prolonged exposure to IUdR can enhance the therapeutic effect by increasing the number of cycling cells that incorporate the Auger emitter.

Supporting Evidence

  • Auger electron emitters cause maximal damage to cells in their immediate vicinity.
  • IUdR is preferentially incorporated into the DNA of rapidly dividing tumor cells.
  • Longer incubation times with IUdR increased the proportion of labeled cells in spheroids.
  • Ki67 labelling index decreased with increasing spheroid diameter.
  • Proliferative heterogeneity affects the efficacy of IUdR-targeted therapy.

Takeaway

This study looks at how a special treatment for brain tumors works better when given over a longer time, helping more sick cells get the medicine they need.

Methodology

The study used multicellular glioma spheroids to assess IUdR incorporation and its relationship with cell proliferation markers.

Limitations

The study's findings may not fully represent in vivo conditions due to the simplification of the spheroid model compared to actual tumors.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication